ORGO
HealthcareOrganogenesis Holdings Inc.
$4.41
$-0.22 (-4.85%)
Jan 5, 2026
Price History (1Y)
Analysis
Organogenesis Holdings Inc. is a healthcare company that specializes in drug manufacturing and operates within the specialty & generic industry. The company has a market capitalization of $559.68 million and employs 869 individuals. The company's financial health indicates that it generates significant revenue, with $465.22 million reported over the trailing twelve months. However, net income is negative at -$9,225,000. Gross margin stands at 74.5%, while operating margin and profit margin are lower at 14.7% and 0.2%, respectively. Return on equity (ROE) is 0.3%, and return on assets (ROA) is 0.2%. The company's balance sheet shows a debt-to-equity ratio of 10.57, with cash reserves of $63.74 million against debt of $40.81 million. The company's valuation is reflected in its forward P/E ratio of 25.94 and price to book ratio of 2.19. Revenue growth over the past year has been significant at 31.0%, although earnings growth was lower at 22.2%. The dividend yield is not applicable as the payout ratio is 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, a dual-layered amniotic tissue graft used to treat chronic and acute wounds. It also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; TransCyte, a bioengineered tissue scaffold that promotes burn healing; and PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications. In addition, the company develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $559.68M
- P/E Ratio
- N/A
- 52-Week High
- $7.08
- 52-Week Low
- $2.61
- Avg Volume
- 1.80M
- Beta
- 1.38
Company Info
- Exchange
- NCM
- Country
- United States
- Employees
- 869